Jules Noten

M80 is an investor in companies in Benelux and France. We seek out ambitious companies & entrepreneurs that embrace change and with whom we work closely to realize their full potential - often by making smart or better use of proven & novel technologies. Our diverse international team of entrepreneurs, former CEOs, private equity professionals and digital pioneers will inspire, challenge and support companies to generate meaningful value for their customers, employees, owners and investors. We invest in companies with a unique mindset, ready to challenge the status quo, in sectors such as consumer, healthcare, business services and manufacturing. Across Benelux and France we typically focus on companies that have sales between €25m and €300m, EBITDA between €5m and €30m and an enterprise value between €25m and €250m. Our preferred investment range is 10 – 60 million in equity. We are open to transactions where we can be a significant shareholder or the leading investor, aligning closely with founders or family shareholders and management.

Qbic is a seed and early-stage venture capital fund supporting spin-offs and start-ups that valorize research from Qbics knowledge partners. Qbic is one of the largest spin-off funds in Europe managing €190 million in resources over the different funds. Qbic I launched in 2012 and has finalized its portfolio of 18 ventures; Qbic II launched in 2017 and has a portfolio of 19 ventures, and Qbic III launched in 2022 and is currently building its portfolio.

Genano Ltd is a health technology company founded in 1999 in Finland. Genano air purifiers are an efficient way to reduce the health risks of airborne impurities such as microbes, ultrafine particles and volatile organic compounds. Our solutions can address even the most challenging air purification needs, ranging from battling against spread of infectious diseases in healthcare facilities to securing safe study environment to children in schools with severely compromised indoor air quality. Genano’s core advantage is the ability to remove airborne impurities of all sizes – down to nanometer size. The patented technology also eliminates microbes such as viruses, bacteria and mould from the air, and removes gases and odours. SOLUTIONS FOR HEALTHCARE - Infection control in isolation rooms and operating theatres - Protection of immunocompromised patients SOLUTIONS FOR CLEANROOMS AND LABORATORIES - Contamination control of airborne impurities down to nanoscale - Contamination control of VOCS and other gaseous impurities SOLUTIONS FOR INDOOR AIR QUALITY - First-aid for Sick Building Syndrome - Prevention of adverse health effects of air pollution - Improvement of cognitive performance and work efficiency __________________________________________________ Genano is active in more than 20 countries around the world. International sales are mainly realized by our dedicated local partners. The Genano headquarters are located in Finland and other offices in Sweden and Belgium. The performance of Genano Technology has been tested and researched comprehensively in laboratory and real use conditions. Our products are designed and manufactured in Finland, and have been awarded with the Design From Finland mark. Find out more at genano.com

M80 is an investor in companies in Benelux and France. We seek out ambitious companies & entrepreneurs that embrace change and with whom we work closely to realize their full potential - often by making smart or better use of proven & novel technologies. Our diverse international team of entrepreneurs, former CEOs, private equity professionals and digital pioneers will inspire, challenge and support companies to generate meaningful value for their customers, employees, owners and investors. We invest in companies with a unique mindset, ready to challenge the status quo, in sectors such as consumer, healthcare, business services and manufacturing. Across Benelux and France we typically focus on companies that have sales between €25m and €300m, EBITDA between €5m and €30m and an enterprise value between €25m and €250m. Our preferred investment range is 10 – 60 million in equity. We are open to transactions where we can be a significant shareholder or the leading investor, aligning closely with founders or family shareholders and management.

As a pioneer in European mid-market private equity, Rivean Capital has been partnering with aspiring management teams to cultivate differentiated opportunities for 40 years. With €5 billion under management, Rivean has executed over 250 transactions, guiding the transformation of compelling businesses with complex opportunity sets and helping to execute creative growth solutions for aspiring business leaders. The firm has offices in Belgium, Germany, Italy, the Netherlands, and Switzerland, creating a distinctly local presence that allows for alignment and engagement with management teams while maintaining a global reach for international M&A, organic growth initiatives, and structural enhancements to bolster winning platforms.

Qbic is a seed and early-stage venture capital fund supporting spin-offs and start-ups that valorize research from Qbics knowledge partners. Qbic is one of the largest spin-off funds in Europe managing €190 million in resources over the different funds. Qbic I launched in 2012 and has finalized its portfolio of 18 ventures; Qbic II launched in 2017 and has a portfolio of 19 ventures, and Qbic III launched in 2022 and is currently building its portfolio.

3i is a leading international investment company with two complementary businesses, Private Equity and Infrastructure, specialising in core investment markets in northern Europe and North America. We provide our shareholders with access to the higher growth potential of mid-market unquoted companies. We use our strong balance sheet and our expertise in specific sectors and geographies to realise this potential and aim to generate mid to high teens returns for our shareholders. We back entrepreneurs and management teams of mid-market businesses in Europe and North America. Once invested, we work closely with our portfolio companies to achieve their full potential.

Genano Ltd is a health technology company founded in 1999 in Finland. Genano air purifiers are an efficient way to reduce the health risks of airborne impurities such as microbes, ultrafine particles and volatile organic compounds. Our solutions can address even the most challenging air purification needs, ranging from battling against spread of infectious diseases in healthcare facilities to securing safe study environment to children in schools with severely compromised indoor air quality. Genano’s core advantage is the ability to remove airborne impurities of all sizes – down to nanometer size. The patented technology also eliminates microbes such as viruses, bacteria and mould from the air, and removes gases and odours. SOLUTIONS FOR HEALTHCARE - Infection control in isolation rooms and operating theatres - Protection of immunocompromised patients SOLUTIONS FOR CLEANROOMS AND LABORATORIES - Contamination control of airborne impurities down to nanoscale - Contamination control of VOCS and other gaseous impurities SOLUTIONS FOR INDOOR AIR QUALITY - First-aid for Sick Building Syndrome - Prevention of adverse health effects of air pollution - Improvement of cognitive performance and work efficiency __________________________________________________ Genano is active in more than 20 countries around the world. International sales are mainly realized by our dedicated local partners. The Genano headquarters are located in Finland and other offices in Sweden and Belgium. The performance of Genano Technology has been tested and researched comprehensively in laboratory and real use conditions. Our products are designed and manufactured in Finland, and have been awarded with the Design From Finland mark. Find out more at genano.com